Glenmark Life Sciences Limited

NSEI:GLS Stock Report

Market Cap: ₹103.9b

Glenmark Life Sciences Past Earnings Performance

Past criteria checks 3/6

Glenmark Life Sciences has been growing earnings at an average annual rate of 13.6%, while the Pharmaceuticals industry saw earnings growing at 17% annually. Revenues have been growing at an average rate of 11.9% per year. Glenmark Life Sciences's return on equity is 20.2%, and it has net margins of 20.6%.

Key information

13.6%

Earnings growth rate

8.2%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate11.9%
Return on equity20.2%
Net Margin20.6%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

Aug 07
Glenmark Life Sciences Limited Recorded A 7.3% Miss On Revenue: Analysts Are Revisiting Their Models

A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

May 10
A Look At The Fair Value Of Glenmark Life Sciences Limited (NSE:GLS)

Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

Feb 15
Why Investors Shouldn't Be Surprised By Glenmark Life Sciences Limited's (NSE:GLS) Low P/E

Revenue & Expenses Breakdown

How Glenmark Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:GLS Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2422,8324,7092,5820
31 Dec 2323,6795,1932,3910
30 Sep 2323,3595,0552,1660
30 Jun 2322,4984,9371,8790
31 Mar 2321,6124,6701,8960
31 Dec 2220,5404,1951,8120
30 Sep 2220,3574,1821,7680
30 Jun 2220,8824,2651,7220
31 Mar 2221,2324,1871,7440
31 Dec 2120,7634,2451,7330
30 Sep 2120,5414,1421,6690
30 Jun 2120,1313,7141,6080
31 Mar 2118,8523,5161,5530
31 Mar 2015,3733,1311,5450
31 Mar 198,8641,9561,1690
31 Mar 182-420

Quality Earnings: GLS has high quality earnings.

Growing Profit Margin: GLS's current net profit margins (20.6%) are lower than last year (21.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GLS's earnings have grown by 13.6% per year over the past 5 years.

Accelerating Growth: GLS's earnings growth over the past year (0.8%) is below its 5-year average (13.6% per year).

Earnings vs Industry: GLS earnings growth over the past year (0.8%) did not outperform the Pharmaceuticals industry 18%.


Return on Equity

High ROE: GLS's Return on Equity (20.2%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.